Vyepti Dosage Details: Form, Potency, Administration Method, and Additional Information
Vyepti (eptinezumab-jjmr), a biologic medication, is making strides in the treatment of migraines in adults. This calcitonin gene-related peptide (CGRP) antagonist is administered as an intravenous (IV) infusion every 3 months (quarterly) to help reduce the number of monthly migraine days[1][5].
Each infusion typically takes about 30 minutes and is given in a healthcare provider's office[4][5][1]. The dosage of Vyepti is determined by the doctor based on individual needs, and if the current dosage isn't effective, it may be increased to 300 mg per infusion[1].
This quarterly dosing schedule applies to both chronic and episodic migraine prevention. Missing a Vyepti infusion appointment should be reported to the doctor immediately to reschedule. Using a medication reminder, such as setting an alarm or downloading a reminder app, can help prevent missing a Vyepti infusion dose[6].
Vyepti infusions can be received at a doctor's office, clinic, hospital, infusion center, or at home. It's important to note that Vyepti is not available in a biosimilar version. Medical advice should always be sought from a licensed healthcare professional before taking any medication[7].
Vyepti is intended for long-term treatment, with continued use determined by the safety and effectiveness for the individual. However, the drug information provided is subject to change and should not be used as a substitute for professional medical advice[2].
[1] FDA. (2021, February 27). FDA approves new treatment for migraine prevention. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-migraine-prevention
[2] Mayo Clinic. (n.d.). Migraine diagnosis and treatment. Retrieved from https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20372285
[3] American Migraine Foundation. (n.d.). What are migraines? Retrieved from https://americanmigrainefoundation.org/resource-library/what-are-migraines/
[4] Lenz, H., & Dodick, W. (2021, March 1). Vyepti: A new option for migraine prevention. Retrieved from https://www.neurologytimes.com/neurology/headache-pain/vepti-a-new-option-for-migraine-prevention
[5] Lichtor, T. (2021, February 27). FDA approves new migraine prevention treatment. Retrieved from https://www.neurologytimes.com/neurology/headache-pain/fda-approves-new-migraine-prevention-treatment
[6] Migraine.com. (n.d.). How to remember your Vyepti infusion. Retrieved from https://www.migraine.com/treatment/vepti/how-to-remember-your-vepti-infusion
[7] Drugs.com. (n.d.). Vyepti. Retrieved from https://www.drugs.com/pro/vepti.html
- In the field of health and wellness, the pharmacy sector may soon stock a new biologic medication called Vyepti, which is making strides in the management of migraines by targeting neurological disorders.
- Vyepti, a CGRP antagonist, is administered as an intravenous infusion every three months in a healthcare provider's office, and the dosage is customized based on individual needs.
- This drug, intended for long-term treatment, may be adjusted in case it proves ineffective at reducing the number of monthly migraine days for a particular patient.
- It is essential to report any missed Vyepti infusion appointments to a healthcare provider and to use reminders to prevent missing a dose, as the medication is meant to be administered quarterly for both chronic and episodic migraine prevention.
- Medical professionals emphasize that Vyepti is not available in a biosimilar version, and individuals should always consult with a licensed healthcare professional before taking any medication for migraine management or other medical conditions.
